David E Neal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5283346/publications.pdf

Version: 2024-02-01

378 papers	31,808 citations	4955 84 h-index	5820 161 g-index
396 all docs	396 docs citations	396 times ranked	35910 citing authors

#	Article	IF	Citations
1	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 2016, 375, 1415-1424.	13.9	2,101
2	The evolutionary history of lethal metastatic prostate cancer. Nature, 2015, 520, 353-357.	13.7	1,185
3	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. New England Journal of Medicine, 2016, 375, 1425-1437.	13.9	962
4	Multiple newly identified loci associated with prostate cancer susceptibility. Nature Genetics, 2008, 40, 316-321.	9.4	796
5	CD133, a novel marker for human prostatic epithelial stem cells. Journal of Cell Science, 2004, 117, 3539-3545.	1.2	714
6	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nature Genetics, 2018, 50, 928-936.	9.4	652
7	The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal, 2011, 30, 2719-2733.	3.5	530
8	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nature Genetics, 2013, 45, 385-391.	9.4	492
9	Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer. Prostate, 2004, 59, 177-189.	1.2	475
10	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study * Commentary: presenting unbiased information to patients can be difficult. BMJ: British Medical Journal, 2002, 325, 766-770.	2.4	461
11	Overexpression of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. International Journal of Cancer, 2011, 128, 574-586.	2.3	420
12	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nature Genetics, 2014, 46, 1103-1109.	9.4	408
13	Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nature Genetics, 2015, 47, 736-745.	9.4	395
14	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nature Genetics, 2009, 41, 1116-1121.	9.4	389
15	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. Nature Genetics, 2015, 47, 367-372.	9.4	380
16	The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man. Cancer Cell, 2013, 23, 35-47.	7.7	354
17	Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. Science, 2014, 345, 1251343.	6.0	348
18	The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer, 1990, 65, 1619-1625.	2.0	336

#	Article	IF	Citations
19	Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. ELife, 2014, 3, .	2.8	318
20	Identification and isolation of human prostate epithelial stem cells based on Î±2Î²1-integrin expression. Journal of Cell Science, 2001, 114, 3865-3872.	1.2	316
21	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, 2015, 6, 6605.	5.8	312
22	Multiple Loci With Different Cancer Specificities Within the 8q24 Gene Desert. Journal of the National Cancer Institute, 2008, 100, 962-966.	3.0	306
23	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality. JAMA - Journal of the American Medical Association, 2018, 319, 883.	3.8	296
24	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncology, The, 2014, 15, 1521-1532.	5.1	291
25	Multiple loci on 8q24 associated with prostate cancer susceptibility. Nature Genetics, 2009, 41, 1058-1060.	9.4	273
26	Tip60 and Histone Deacetylase 1 Regulate Androgen Receptor Activity through Changes to the Acetylation Status of the Receptor. Journal of Biological Chemistry, 2002, 277, 25904-25913.	1.6	268
27	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 2011, 43, 785-791.	9.4	265
28	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. Nature Genetics, 2021, 53, 65-75.	9.4	264
29	Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers. International Journal of Cancer, 2011, 128, 562-573.	2.3	260
30	Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer. Nature Medicine, 1996, 2, 912-917.	15.2	255
31	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nature Genetics, 2011, 43, 1098-1103.	9.4	251
32	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 2011, 30, 3019-3027.	3.5	247
33	New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Reports, 2007, 8, 871-878.	2.0	240
34	Prostate-cancer mortality in the USA and UK in 1975â€“2004: an ecological study. Lancet Oncology, The, 2008, 9, 445-452.	5.1	231
35	Screening for prostate cancer. Lancet, The, 2003, 361, 1122-1128.	6.3	227
36	Tip60 Is a Nuclear Hormone Receptor Coactivator. Journal of Biological Chemistry, 1999, 274, 17599-17604.	1.6	225

#	Article	IF	Citations
37	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ: British Medical Journal, 2012, 344, d7894-d7894.	2.4	211
38	Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene, 2003, 22, 2466-2477.	2.6	206
39	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1109-1118.	5.1	205
40	Structural basis for the nuclear import of the human androgen receptor. Journal of Cell Science, 2008, 121, 957-968.	1.2	193
41	Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Molecular Cancer, 2010, 9, 59.	7.9	183
42	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nature Genetics, 2018, 50, 682-692.	9.4	182
43	Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications, 2017, 8, 374.	5.8	180
44	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nature Genetics, 2012, 44, 1326-1329.	9.4	178
45	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
46	RB1 Methylation by SMYD2 Enhances Cell Cycle Progression through an Increase of RB1 Phosphorylation. Neoplasia, 2012, 14, 476-IN8.	2.3	169
47	Genome-wide association study identifies new prostate cancer susceptibility loci. Human Molecular Genetics, 2011, 20, 3867-3875.	1.4	160
48	Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Research, 2005, 33, 13-26.	6.5	158
49	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	7.7	157
50	It's not just what you say, it's also how you say it: Opening the â€˜black boxâ€™ of informed consent appointments in randomised controlled trials. Social Science and Medicine, 2009, 68, 2018-2028.	1.8	154
51	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ: British Medical Journal, 2018, 360, j5757.	2.4	153
52	Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochemical Journal, 2010, 428, 439-450.	1.7	149
53	Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2052-2061.	1.1	148
54	Original Articles: Bladder Cancer: Long-Term Outcome Related to Epidermal Growth Factor Receptor Status in Bladder Cancer. Journal of Urology, 1995, 153, 919-925.	0.2	147

#	Article	IF	Citations
55	Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study. Journal of the National Cancer Institute, 2015, 107, .	3.0	146
56	Circulating Folate, Vitamin B12, Homocysteine, Vitamin B12 Transport Proteins, and Risk of Prostate Cancer: a Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1632-1642.	1.1	142
57	Genetic Correction of PSA Values Using Sequence Variants Associated with PSA Levels. Science Translational Medicine, 2010, 2, 62ra92.	5.8	140
58	Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. , 1998, 37, 149-160.		135
59	FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene, 1999, 18, 2755-2761.	2.6	133
60	Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin. Molecular Endocrinology, 2000, 14, 1618-1626.	3.7	133
61	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. Journal of Clinical Epidemiology, 2009, 62, 29-36.	2.4	133
62	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. Human Molecular Genetics, 2013, 22, 5056-5064.	1.4	130
63	Reducing Warm Ischaemia Time During Laparoscopic Partial Nephrectomy: A Prospective Comparison of Two Renal Closure Techniques. European Urology, 2007, 52, 1164-1169.	0.9	127
64	Are dietâ€“prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-1 and IGFBP-3 in healthy middle-aged men. British Journal of Cancer, 2003, 88, 1682-1686.	2.9	123
65	Prognostic and Therapeutic Impact of Argininosuccinate Synthetase 1 Control in Bladder Cancer as Monitored Longitudinally by PET Imaging. Cancer Research, 2014, 74, 896-907.	0.4	122
66	Symptoms, unmet needs, psychological wellâ€being and health status in survivors of prostate cancer: implications for redesigning followâ€up. BJU International, 2016, 117, E10-9.	1.3	120
67	Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics, 2016, 48, 387-397.	9.4	119
68	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. Contemporary Clinical Trials, 2003, 24, 272-282.	2.0	118
69	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Human Molecular Genetics, 2013, 22, 408-415.	1.4	118
70	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. Cancer Research, 2016, 76, 2288-2300.	0.4	117
71	A Multinational, Multi-institutional Study Comparing Positive Surgical Margin Rates Among 22 393 Open, Laparoscopic, and Robot-assisted Radical Prostatectomy Patients. European Urology, 2014, 66, 450-456.	0.9	116
72	Enhanced Expression of EHMT2 Is Involved in the Proliferation of Cancer Cells through Negative Regulation of SIAH1. Neoplasia, 2011, 13, 676-IN10.	2.3	112

#	Article	IF	Citations
73	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. American Journal of Clinical Nutrition, 2015, 102, 1142-1157.	2.2	107
74	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology, 2020, 77, 320-330.	0.9	107
75	Expression of S100A4 protein is associated with metastasis and reduced survival in human bladder cancer. Journal of Pathology, 2002, 196, 292-299.	2.1	104
76	Genetic and functional analyses implicate the NUDT11 , HNF1B , and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11252-11257.	3.3	102
77	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. World Journal of Urology, 2012, 30, 149-155.	1.2	101
78	Engrailed-2 (EN2): A Tumor Specific Urinary Biomarker for the Early Diagnosis of Prostate Cancer. Clinical Cancer Research, 2011, 17, 1090-1098.	3.2	100
79	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Human Molecular Genetics, 2013, 22, 2520-2528.	1.4	100
80	A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy. Journal of Pathology, 2015, 236, 517-530.	2.1	99
81	Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Molecular Cancer, 2011, 10, 65.	7.9	97
82	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. European Urology, 2015, 67, 993-1005.	0.9	96
83	Exploring treatment preferences facilitated recruitment to randomized controlled trials. Journal of Clinical Epidemiology, 2011, 64, 1127-1136.	2.4	93
84	Histone Lysine Methyltransferase Wolf-Hirschhorn Syndrome Candidate 1 Is Involved in Human Carcinogenesis through Regulation of the Wnt Pathway. Neoplasia, 2011, 13, 887-IN11.	2.3	92
85	Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2528-2539.	1.1	89
86	Key considerations for the experimental training and evaluation of cancer odour detection dogs: lessons learnt from a double-blind, controlled trial of prostate cancer detection. BMC Urology, 2014, 14, 22.	0.6	89
87	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. Nature Communications, 2018, 9, 2256.	5.8	88
88	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genetics in Medicine, 2015, 17, 789-795.	1.1	87
89	The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group. Clinical Cancer Research, 2010, 16, 4374-4381.	3.2	86
90	The JmjC domainâ€containing histone demethylase KDM3A is a positive regulator of the G₁/S transition in cancer cells via transcriptional regulation of the HOXA1 gene. International Journal of Cancer, 2012, 131, E179-89.	2.3	85

#	Article	IF	Citations
91	Estrogen receptor beta in prostate cancer: friend or foe?. Endocrine-Related Cancer, 2014, 21, T219-T234.	1.6	85
92	Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene, 1997, 15, 1115-1120.	2.6	83
93	Tip60 Is a Co-activator Specific for Class I Nuclear Hormone Receptors. Journal of Biological Chemistry, 2001, 276, 46841-46848.	1.6	83
94	Height and Prostate Cancer Risk: A Large Nested Case-Control Study (ProtecT) and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2325-2336.	1.1	83
95	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. Human Genetics, 2011, 129, 687-694.	1.8	83
96	A RANDOMIZED TRIAL COMPARING TRANSURETHRAL RESECTION OF THE PROSTATE, LASER THERAPY AND CONSERVATIVE TREATMENT OF MEN WITH SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC ENLARGEMENT: THE CLasP STUDY. Journal of Urology, 2000, 164, 65-70.	0.2	81
97	Psychological Impact of Prostate Biopsy: Physical Symptoms, Anxiety, and Depression. Journal of Clinical Oncology, 2013, 31, 4235-4241.	0.8	81
98	Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer. Clinical Cancer Research, 2004, 10, 4874-4884.	3.2	78
99	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. British Journal of Cancer, 2010, 102, 1335-1340.	2.9	77
100	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. Cancer Causes and Control, 2015, 26, 1603-1616.	0.8	77
101	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. , 1998, 37, 223-229.		75
102	LYRIC/AEG-1 Is Targeted to Different Subcellular Compartments by Ubiquitinylation and Intrinsic Nuclear Localization Signals. Clinical Cancer Research, 2009, 15, 3003-3013.	3.2	75
103	Regulation of FGF8 expression by the androgen receptor in human prostate cancer. Oncogene, 2002, 21, 5069-5080.	2.6	74
104	HES6 drives a critical <scp>AR</scp> transcriptional programme to induce castrationâ€resistant prostate cancer through activation of an <scp>E</scp>2<scp>F</scp>1â€mediated cell cycle network. EMBO Molecular Medicine, 2014, 6, 651-661.	3.3	74
105	The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine. PLoS ONE, 2010, 5, e13363.	1.1	73
106	Epidermal Growth Factor Receptor and Bladder Cancer: A Review. Urologia Internationalis, 1992, 48, 365-371.	0.6	72
107	Populationâ€based prostateâ€specific antigen testing in the UK leads to a stage migration of prostate cancer. BJU International, 2009, 104, 1592-1598.	1.3	69
108	Cancer, Chemistry, and the Cell: Molecules that Interact with the Neurotensin Receptors. ACS Chemical Biology, 2009, 4, 503-525.	1.6	69

#	Article	IF	Citations
109	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. Genome Research, 2015, 25, 814-824.	2.4	69
110	Who can best recruit to randomized trials?. Journal of Clinical Epidemiology, 2003, 56, 605-609.	2.4	68
111	Blood lipids and prostate cancer: a Mendelian randomization analysis. Cancer Medicine, 2016, 5, 1125-1136.	1.3	68
112	Transcutaneous Electrical Nerve Stimulation and Temporary S3 Neuromodulation in Idiopathic Detrusor Instability. Journal of Urology, 1996, 155, 2005-2011.	0.2	67
113	Alterations in Î²â€catenin expression and localization in prostate cancer. Prostate, 2008, 68, 1196-1205.	1.2	67
114	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. Human Molecular Genetics, 2015, 24, 5589-5602.	1.4	67
115	Huntingtin interacting protein 1 modulates the transcriptional activity of nuclear hormone receptors. Journal of Cell Biology, 2005, 170, 191-200.	2.3	66
116	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World Journal of Urology, 2012, 30, 181-187.	1.2	66
117	Conventional Urodynamics and Ambulatory Monitoring in the Definition and Management of Bladder Outflow Obstruction. Journal of Urology, 1996, 155, 506-511.	0.2	65
118	Prostate cancer: to screen or not to screen?. Lancet Oncology, The, 2000, 1, 17-24.	5.1	65
119	Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2874-2881.	1.1	64
120	The histone methyltransferase Wolfâ€“Hirschhorn syndrome candidate 1â€like 1 (WHSC1L1) is involved in human carcinogenesis. Genes Chromosomes and Cancer, 2013, 52, 126-139.	1.5	64
121	Prostateâ€specific antigen testing rates remain low in UK general practice: a crossâ€sectional study in six English cities. BJU International, 2011, 108, 1402-1408.	1.3	63
122	Associations of circulating 25â€hydroxyvitamin D with prostate cancer diagnosis, stage and grade. International Journal of Cancer, 2012, 131, 1187-1196.	2.3	63
123	The Histone Demethylase JMJD2B Plays an Essential Role in Human Carcinogenesis through Positive Regulation of Cyclin-Dependent Kinase 6. Cancer Prevention Research, 2011, 4, 2051-2061.	0.7	62
124	Surgical margin length and location affect recurrence rates after robotic prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 109.e7-109.e13.	0.8	61
125	Associations between an Obesity Related Genetic Variant (FTO rs9939609) and Prostate Cancer Risk. PLoS ONE, 2010, 5, e13485.	1.1	61
126	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. British Journal of Cancer, 2009, 100, 1198-1204.	2.9	58

#	Article	IF	Citations
127	Tumor Necrosis Factor Receptor Expression and Signaling in Renal Cell Carcinoma. American Journal of Pathology, 2010, 177, 943-954.	1.9	58
128	A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer. British Journal of Cancer, 2009, 100, 426-430.	2.9	57
129	Nuclear <scp>ARRB</scp> 1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO Journal, 2014, 33, 1365-1382.	3.5	57
130	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. Journal of Urology, 2000, 163, 630-633.	0.2	56
131	Control of Human PIRH2 Protein Stability. Journal of Biological Chemistry, 2004, 279, 11696-11704.	1.6	56
132	Oral ciprofloxacin or trimethoprim reduces bacteriuria after flexible cystoscopy. BJU International, 2007, 100, 826-829.	1.3	56
133	Association of diabetes mellitus with prostate cancer: Nested caseâ€“control study (Prostate testing) Tj ETQq1 1 0.784314 rgBT /Ove	2.3	56
134	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. Cancer Discovery, 2015, 5, 368-379.	7.7	56
135	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1121-1129.	1.1	56
136	The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. European Urology, 2016, 70, 214-218.	0.9	56
137	The potential value of microseminoproteinâ€Î²2 as a prostate cancer biomarker and therapeutic target. Prostate, 2010, 70, 333-340.	1.2	55
138	aFGF immunoreactivity in prostate cancer and its co-localization with bFGF and FGF8. , 1999, 189, 564-569.		54
139	Prediction of individual genetic risk to prostate cancer using a polygenic score. Prostate, 2015, 75, 1467-1474.	1.2	54
140	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975â€“2004. BJU International, 2008, 101, 547-555.	1.3	53
141	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes and Control, 2020, 31, 431-449.	0.8	53
142	Do Height-Related Variations in Insulin-Like Growth Factors Underlie the Associations of Stature with Adult Chronic Disease?. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 213-218.	1.8	52
143	Patientâ€reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. BJU International, 2016, 118, 869-879.	1.3	52
144	The Scaffolding Protein RACK1 Interacts with Androgen Receptor and Promotes Cross-talk through a Protein Kinase C Signaling Pathway. Journal of Biological Chemistry, 2003, 278, 46087-46093.	1.6	51

#	Article	IF	Citations
145	Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. International Journal of Cancer, 2004, 108, 887-892.	2.3	51
146	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. Prostate, 2008, 68, 661-674.	1.2	51
147	Evaluating Genetic Risk for Prostate Cancer among Japanese and Latinos. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2048-2058.	1.1	51
148	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. International Journal of Epidemiology, 2019, 48, 1416-1424.	0.9	51
149	Circulating Insulin-Like Growth Factors and IGF-Binding Proteins in PSA-Detected Prostate Cancer: The Large Caseâ€“Control Study ProtecT. Cancer Research, 2012, 72, 503-515.	0.4	50
150	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. Trials, 2014, 15, 323.	0.7	50
151	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. Nature Communications, 2016, 7, 10979.	5.8	50
152	Androgen Receptor Nuclear Translocation Is Facilitated by the f-Actin Cross-Linking Protein Filamin. Molecular Endocrinology, 2000, 14, 1618-1626.	3.7	50
153	Life course sun exposure and risk of prostate cancer: Populationâ€based nested caseâ€control study and metaâ€analysis. International Journal of Cancer, 2009, 125, 1414-1423.	2.3	49
154	Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. BMJ: British Medical Journal, 2010, 340, c1928-c1928.	2.4	49
155	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. European Urology, 2019, 76, 329-337.	0.9	48
156	Circulating Folate and Vitamin B12 and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. European Urology, 2016, 70, 941-951.	0.9	46
157	Identification of potential therapeutic targets in prostate cancer through a crossâ€species approach. EMBO Molecular Medicine, 2018, 10, .	3.3	46
158	Continuing Controversy Over Monitoring Men With Localized Prostate Cancer: A Systematic Review of Programs in the Prostate Specific Antigen Era. Journal of Urology, 2006, 176, 439-449.	0.2	45
159	First 500 cases of roboticâ€assisted laparoscopic radical prostatectomy from a single UK centre: learning curves of two surgeons. BJU International, 2011, 108, 739-747.	1.3	45
160	Salt-Inducible Kinase 2 Regulates Mitotic Progression and Transcription in Prostate Cancer. Molecular Cancer Research, 2015, 13, 620-635.	1.5	45
161	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. BJU International, 2003, 91, 331-336.	1.3	44
162	Asporin is a stromally expressed marker associated with prostate cancer progression. British Journal of Cancer, 2017, 116, 775-784.	2.9	44

#	Article	IF	Citations
163	Putative involvement of the histone acetyltransferase Tip60 in ribosomal gene transcription. Nucleic Acids Research, 2004, 32, 1654-1665.	6.5	43
164	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. Nature Communications, 2018, 9, 4616.	5.8	43
165	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. BMC Medicine, 2016, 14, 66.	2.3	42
166	Associations of lower urinary tract symptoms with prostateâ€specific antigen levels, and screenâ€detected localized and advanced prostate cancer: a caseâ€control study nested within the UK populationâ€based ProtecT (Prostate testing for cancer and Treatment) study. BJU International, 2008, 102, 1400-1406.	1.3	41
167	Decision-Making about PSA Testing and Prostate Biopsies: A Qualitative Study Embedded in a Primary Care Randomised Trial. European Urology, 2008, 53, 1186-1193.	0.9	41
168	Associations of aspirin, nonsteroidal antiâ€inflammatory drug and paracetamol use with PSAâ€detected prostate cancer: Findings from a large, populationâ€based, caseâ€“control study (the ProtecT study). International Journal of Cancer, 2011, 128, 1442-1448.	2.3	41
169	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology, 2017, 71, 381-388.	0.9	41
170	Keratinocyte growth factor activates p38 MAPK to induce stress fibre formation in human prostate DU145 cells. Oncogene, 2001, 20, 5359-5365.	2.6	40
171	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU International, 2006, 98, 777-782.	1.3	40
172	Malignant germ cell tumours in the elderly: a histopathological review of 50 cases in men aged 60 years or over. Modern Pathology, 2008, 21, 54-59.	2.9	40
173	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. BMC Family Practice, 2014, 15, 81.	2.9	40
174	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications, 2021, 12, 1236.	5.8	40
175	A new look towards BAC-based array CGH through a comprehensive comparison with oligo-based array CGH. BMC Genomics, 2007, 8, 84.	1.2	39
176	The transcriptional programme of the androgen receptor (<scp>AR</scp>) in prostate cancer. BJU International, 2014, 113, 358-366.	1.3	38
177	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. British Journal of Cancer, 2016, 115, 90-94.	2.9	38
178	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. European Urology Oncology, 2021, 4, 570-579.	2.6	38
179	HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. Oncotarget, 2016, 7, 74734-74746.	0.8	38
180	High-Resolution Array-Based Comparative Genomic Hybridization of Bladder Cancers IdentifiesMouse Double Minute 4(MDM4) as an Amplification Target Exclusive ofMDM2andTP53. Clinical Cancer Research, 2008, 14, 2527-2534.	3.2	37

#	Article	IF	Citations
181	Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute, 2016, 108, djv371.	3.0	37
182	Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors. European Urology, 2017, 72, 22-31.	0.9	37
183	RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate, 2007, 67, 638-644.	1.2	36
184	Men with prostate cancer make positive dietary changes following diagnosis and treatment. Cancer Causes and Control, 2013, 24, 1119-1128.	0.8	36
185	Differential C3NET reveals disease networks of direct physical interactions. BMC Bioinformatics, 2011, 12, 296.	1.2	35
186	Basic science aspects of prostate cancer. Seminars in Cancer Biology, 1997, 8, 21-27.	4.3	34
187	Transfection of S100A4 Produces Metastatic Variants of an Orthotopic Model of Bladder Cancer. American Journal of Pathology, 2002, 160, 693-700.	1.9	34
188	Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer. PLoS Genetics, 2014, 10, e1004129.	1.5	34
189	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. PLoS Genetics, 2017, 13, e1007001.	1.5	34
190	Comparative efficacy and safety of treatments for localised prostate cancer: an application of network meta-analysis. BMJ Open, 2014, 4, e004285.	0.8	33
191	Adherence to Dietary and Lifestyle Recommendations and Prostate Cancer Risk in the Prostate Testing for Cancer and Treatment (ProtecT) Trial. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2066-2077.	1.1	33
192	The ETS family member GABPÎ± modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Research, 2014, 42, 6256-6269.	6.5	33
193	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested caseâ€“control study. Cancer Causes and Control, 2015, 26, 205-218.	0.8	33
194	Pro-neural transcription factors as cancer markers. BMC Medical Genomics, 2008, 1, 17.	0.7	32
195	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. Cancer Causes and Control, 2012, 23, 907-917.	0.8	32
196	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes and Control, 2012, 23, 347-354.	0.8	32
197	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prevention Research, 2018, 11, 687-696.	0.7	32
198	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. BJU International, 2020, 125, 506-514.	1.3	32

#	Article	IF	Citations
199	Screening for prostate cancer in the UK. BMJ: British Medical Journal, 2001, 323, 763-764.	2.4	31
200	Reply to â€œVariation in KLK genes, prostate-specific antigen and risk of prostate cancerâ€. Nature Genetics, 2008, 40, 1035-1036.	9.4	31
201	Alcohol consumption and PSAâ€detected prostate cancer riskâ€"A caseâ€control nested in the ProtecT study. International Journal of Cancer, 2013, 132, 2176-2185.	2.3	31
202	Response of Degarelix treatment in human prostate cancer monitored by HR-MAS 1H NMR spectroscopy. Metabolomics, 2016, 12, 120.	1.4	31
203	Androgen regulation of ornithine decarboxylase in human prostatic cells identified using differential display. FEBS Letters, 1997, 405, 328-332.	1.3	30
204	A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate, 2007, 67, 190-202.	1.2	30
205	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. Cancer Causes and Control, 2013, 24, 323-334.	0.8	30
206	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 635-643.	0.8	30
207	DESNT: A Poor Prognosis Category of Human Prostate Cancer. European Urology Focus, 2018, 4, 842-850.	1.6	30
208	Surface Localization of Sacral Foramina for Neuromodulation of Bladder Function. European Urology, 1996, 29, 90-98.	0.9	29
209	The molecular pathology of urological malignancies. , 1997, 183, 380-387.		29
210	Infective complications after transrectal ultrasoundâ€guided prostate biopsy following a new protocol for antibiotic prophylaxis aimed at reducing hospitalâ€acquired infections. BJU International, 2011, 108, 1597-1602.	1.3	29
211	Validation of the Hospital Episode Statistics Outpatient Dataset in England. Pharmacoeconomics, 2016, 34, 161-168.	1.7	29
212	Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts: results from the prostate biopsy collaborative group. World Journal of Urology, 2014, 32, 185-191.	1.2	28
213	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. International Journal of Cancer, 2017, 140, 75-85.	2.3	28
214	Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies. PLoS ONE, 2010, 5, e10858.	1.1	28
215	Genome-Wide Association Study of Prostate Cancerâ€"Specific Survival. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1796-1800.	1.1	27
216	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. Oncologist, 2016, 21, 716-722.	1.9	27

#	Article	IF	Citations
217	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	1.1	27
218	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. BMJ Open, 2017, 7, e017729.	0.8	27
219	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. Journal of Medical Ethics, 2008, 34, 37-40.	1.0	26
220	The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. Cancer Causes and Control, 2010, 21, 1829-1842.	0.8	26
221	Genetic Variation in Prostate-Specific Antigenâ€"Detected Prostate Cancer and the Effect of Control Selection on Genetic Association Studies. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1356-1365.	1.1	26
222	Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). British Journal of Cancer, 2014, 110, 2829-2836.	2.9	26
223	Incidence of needleâ€tract seeding following prostate biopsy for suspected cancer: a review of the literature. BJU International, 2015, 115, 698-704.	1.3	26
224	Assessing the role of insulinâ€like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. International Journal of Cancer, 2016, 139, 1520-1533.	2.3	26
225	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. European Urology, 2017, 72, 509-518.	0.9	26
226	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: Opportunities for lifestyle modification. International Journal of Cancer, 2015, 137, 1509-1515.	2.3	25
227	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. Cancer Research, 2019, 79, 274-285.	0.4	25
228	Independence of HIF1a and androgen signaling pathways in prostate cancer. BMC Cancer, 2020, 20, 469.	1.1	25
229	The role of surgery in highâ€risk localised prostate cancer. BJU International, 2012, 109, 648-658.	1.3	24
230	Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-Analysis. PLoS ONE, 2014, 9, e110569.	1.1	24
231	Late Imaging with [1-¹¹C]Acetate Improves Detection of Tumor Fatty Acid Synthesis with PET. Journal of Nuclear Medicine, 2014, 55, 1144-1149.	2.8	24
232	Is continent diversion using the Mitrofanoff principle a viable longâ€term option for adults requiring bladder replacement?. BJU International, 2008, 102, 236-240.	1.3	23
233	Identification of new genetic risk factors for prostate cancer. Asian Journal of Andrology, 2009, 11, 49-55.	0.8	23
234	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. British Journal of Cancer, 2011, 104, 875-881.	2.9	23

#	Article	IF	Citations
235	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes and Control, 2012, 23, 1865-1873.	0.8	23
236	Downregulation of Androgen Receptor Transcription by Promoter G-Quadruplex Stabilization as a Potential Alternative Treatment for Castrate-Resistant Prostate Cancer. Biochemistry, 2013, 52, 1429-1436.	1.2	23
237	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). BMJ Open, 2016, 6, e011063.	0.8	23
238	Misclassification of outcome in caseâ€“control studies: Methods for sensitivity analysis. Statistical Methods in Medical Research, 2016, 25, 2377-2393.	0.7	23
239	Epigenetic and oncogenic regulation of SLC16A7 (MCT2) results in protein over-expression, impacting on signalling and cellular phenotypes in prostate cancer. Oncotarget, 2015, 6, 21675-21684.	0.8	23
240	High level expression of the multidrug resistance (MDRI) gene in the normal bladder urothelium: a potential involvement in protection against carcinogens?. Carcinogenesis, 1996, 17, 601-604.	1.3	22
241	Mucus production after transposition of intestinal segments into the urinary tract. World Journal of Urology, 2004, 22, 178-185.	1.2	22
242	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). Contemporary Clinical Trials, 2006, 27, 413-419.	0.8	22
243	Screening for prostate cancer remains controversial. Lancet, The, 2009, 374, 1482-1483.	6.3	22
244	Prostate cancer metabolite quantification relative to water in ¹Hâ€MRSI in vivo at 3 Tesla. Magnetic Resonance in Medicine, 2011, 65, 914-919.	1.9	22
245	Predictors of Attendance for Prostate-Specific Antigen Screening Tests and Prostate Biopsy. European Urology, 2012, 62, 649-655.	0.9	22
246	Detailed analysis of operating time learning curves in robotic prostatectomy by a novice surgeon. BJU International, 2012, 109, 1074-1080.	1.3	22
247	Method for sampling tissue for research which preserves pathological data in radical prostatectomy. Prostate, 2013, 73, 194-202.	1.2	22
248	Using Genetic Proxies for Lifecourse Sun Exposure to Assess the Causal Relationship of Sun Exposure with Circulating Vitamin D and Prostate Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 597-606.	1.1	22
249	Insertion of an SVA-E retrotransposon into theCASP8gene is associated with protection against prostate cancer. Human Molecular Genetics, 2016, 25, 1008-1018.	1.4	22
250	No Evidence for Infection of UK Prostate Cancer Patients with XMRV, BK Virus, Trichomonas vaginalis or Human Papilloma Viruses. PLoS ONE, 2012, 7, e34221.	1.1	22
251	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	1.3	22
252	Vitamin B12 malabsorption following bladder reconstruction or diversion with bowel segments. ANZ Journal of Surgery, 2002, 72, 479-482.	0.3	21

#	Article	IF	Citations
253	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 208-216.	1.1	21
254	Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. Urology, 1997, 50, 55-61.	0.5	20
255	Associations of Folate, Vitamin B12, Homocysteine, and Folate-Pathway Polymorphisms with Prostate-Specific Antigen Velocity in Men with Localized Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2833-2838.	1.1	20
256	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the Prostate testing for cancer and Treatment study. Cancer Causes and Control, 2012, 23, 575-588.	0.8	20
257	Serum Insulin-Like Growth Factor-I Is Positively Associated with Serum Prostate-Specific Antigen in Middle-Aged Men without Evidence of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2004, 13, 163-165.	1.1	19
258	Contribution of a Single Repeat PSA Test to Prostate Cancer Risk Assessment: Experience from the ProtecT Study. European Urology, 2008, 53, 777-784.	0.9	19
259	Stage Shift in Psa-detected Prostate Cancers â€“ Effect Modification by Gleason Score. Journal of Medical Screening, 2009, 16, 98-101.	1.1	19
260	Mutation analysis of the MSMB gene in familial prostate cancer. British Journal of Cancer, 2010, 102, 414-418.	2.9	19
261	Associations of Lifestyle Factors and Anthropometric Measures with Repeat PSA Levels During Active Surveillance/Monitoring. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1877-1885.	1.1	19
262	Ryanodine receptors in human bladder smooth muscle. Experimental Physiology, 1999, 84, 41-46.	0.9	18
263	Adhesion of lymphocytes to bladder cancer cells: the role of the Î± E Î² 7 integrin. Cancer Immunology, Immunotherapy, 2002, 51, 483-491.	2.0	18
264	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. BMJ: British Medical Journal, 2007, 335, 1139.	2.4	18
265	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. European Journal of Cancer, 2009, 45, 2569-2573.	1.3	18
266	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. Journal of Clinical Epidemiology, 2011, 64, 628-636.	2.4	18
267	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. British Journal of Cancer, 2011, 105, 931-937.	2.9	18
268	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. BMJ Open, 2015, 5, e008953.	0.8	18
269	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. Journal of Urology, 2017, 197, 607-613.	0.2	18
270	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. Oncotarget, 2016, 7, 21393-21403.	0.8	18

#	Article	IF	Citations
271	ESTABLISHING A ROBOTIC PROSTATECTOMY PROGRAMME: THE IMPACT OF MENTORING USING A STRUCTURED APPROACH. BJU International, 2006, 97, 1143-1144.	1.3	17
272	Labeling and identification of LNCaP cell surface proteins: A pilot study. Prostate, 2007, 67, 943-954.	1.2	17
273	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. British Journal of Cancer, 2009, 101, 390-394.	2.9	17
274	RAS Pathways in Prostate Cancer - Mediators of Hormone Resistance?. Current Cancer Drug Targets, 2010, 10, 834-839.	0.8	17
275	The role of 1.5 <scp>T</scp>esla magnetic resonance imaging in staging prostate cancer. ANZ Journal of Surgery, 2013, 83, 234-238.	0.3	17
276	Investigating the prostate specific antigen, body mass index and age relationship: is an ageâ€“BMI-adjusted PSA model clinically useful?. Cancer Causes and Control, 2016, 27, 1465-1474.	0.8	17
277	Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array. British Journal of Cancer, 2016, 114, 945-952.	2.9	17
278	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. International Journal of Cancer, 2017, 140, 322-328.	2.3	17
279	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). European Journal of Oncology Nursing, 2018, 32, 73-81.	0.9	17
280	Transcriptomic analysis reveals inhibition of androgen receptor activity by AMPK in prostate cancer cells. Oncotarget, 2014, 5, 3785-3799.	0.8	17
281	Transurethral Prostate Resection, Noncontact Laser Therapy or Conservative Management in Men With Symptoms of Benign Prostatic Enlargement? An Economic Evaluation. Journal of Urology, 2002, 168, 2476-2482.	0.2	16
282	PTGS2â€“899G>C and prostate cancer risk: a population-based nested caseâ€“control study (ProtecT) and a systematic review with meta-analysis. Prostate Cancer and Prostatic Diseases, 2009, 12, 296-300.	2.0	16
283	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. Journal of Health Services Research and Policy, 2009, 14, 77-81.	0.8	16
284	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. BMC Health Services Research, 2015, 15, 80.	0.9	16
285	Loss of hSef promotes metastasis through upregulation of EMT in prostate cancer. International Journal of Cancer, 2017, 140, 1881-1887.	2.3	16
286	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 2018, 96, 35-46.	2.4	16
287	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. Cancers, 2020, 12, 3254.	1.7	16
288	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 532-541.	2.0	16

#	Article	IF	Citations
289	PSA testing for prostate cancer improves survivalâ€"but can we do better?. Lancet Oncology, The, 2010, 11, 702-703.	5.1	15
290	Menâ€™s knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. BMC Cancer, 2014, 14, 812.	1.1	15
291	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes and Control, 2018, 29, 383-388.	0.8	15
292	A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer. Oncogene, 2019, 38, 1136-1150.	2.6	15
293	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. British Journal of Cancer, 2020, 123, 1063-1070.	2.9	15
294	A comparative study of peri-operative outcomes for 100 consecutive post-chemotherapy and primary robot-assisted and open retroperitoneal lymph node dissections. World Journal of Urology, 2021, , 1.	1.2	15
295	Detrusor contraction strength in men undergoing prostatectomy. Neurourology and Urodynamics, 1993, 12, 109-121.	0.8	14
296	PSAâ€detected prostate cancer and the potential for dedifferentiationâ€"estimating the proportion capable of progression. International Journal of Cancer, 2011, 128, 1462-1470.	2.3	14
297	Global assessment of network inference algorithms based on available literature of gene/protein interactions. Turkish Journal of Biology, 2013, 37, 547-555.	2.1	14
298	Evolution and oncological outcomes of a contemporary radical prostatectomy practice in a <scp>UK</scp> regional tertiary referral centre. BJU International, 2016, 118, 779-784.	1.3	14
299	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGFâ€I, IGFâ€II, IGFBPâ€1, IGFBPâ€2 and IGFBPâ€3 in a pooled analysis of 16,024 men from 22 studies. International Journal of Cancer, 2019, 145, 3244-3256.	2.3	14
300	The effect of sample size on polygenic hazard models for prostate cancer. European Journal of Human Genetics, 2020, 28, 1467-1475.	1.4	14
301	Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data. PLoS ONE, 2011, 6, e26527.	1.1	14
302	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. Prostate Cancer and Prostatic Diseases, 2022, 25, 755-761.	2.0	14
303	AURKA overexpression accompanies dysregulation of DNA-damage response genes in invasive urothelial cell carcinoma. Cell Cycle, 2008, 7, 3525-3533.	1.3	13
304	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: A case-control study nested within the UK population-based ProtecT (Prostate testing for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	13
305	Androgen deprivation treatment in prostate cancer. BMJ, The, 2013, 346, e8555-e8555.	3.0	13
306	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. Urology, 2004, 64, 317-322.	0.5	12

#	Article	IF	Citations
307	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. Journal of Clinical Epidemiology, 2009, 62, 67-73.	2.4	12
308	Development of a New Method for Monitoring Prostate-Specific Antigen Changes in Men with Localised Prostate Cancer: A Comparison of Observational Cohorts. European Urology, 2010, 57, 446-452.	0.9	12
309	Very Low PSA Concentrations and Deletions of the KLK3 Gene. Clinical Chemistry, 2013, 59, 234-244.	1.5	12
310	Whole blood mRNA in prostate cancer reveals a four-gene androgen regulated panel. Endocrine-Related Cancer, 2016, 23, 797-812.	1.6	12
311	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the) Tj ETQq1 1 0.784314 rgBT /Ove		
312	Selective Targeting of the TPX2 Site of Importinâ€Î± Using Fragmentâ€Based Ligand Design. ChemMedChem, 2015, 10, 1232-1239.	1.6	11
313	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. Journal of Urology, 2018, 199, 1470-1474.	0.2	11
314	The Outcome of Prostatectomy on Chronic Retention of Urine. Journal of Urology, 1991, 146, 1029-1033.	0.2	10
315	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. , 1998, 185, 108-111.		10
316	Screening for prostate cancer. Annals of Oncology, 1998, 9, 1289-1292.	0.6	10
317	Fournier's gangrene. Nature Reviews Urology, 2006, 3, 54-57.	1.4	10
318	Prostateâ€specific antigen testing and prostate biopsy: are selfâ€reported lower urinary tract symptoms and healthâ€related quality of life associated with the decision to undergo these investigations?. BJU International, 2008, 102, 1629-1633.	1.3	10
319	General application of the National Institute for Health and Clinical Excellence (NICE) guidance for active surveillance for men with prostate cancer is not appropriate in unscreened populations. BJU International, 2012, 110, 24-27.	1.3	10
320	PROSPECTIVâ€"a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial: TableÂ1. BMJ Open, 2014, 4, e005186.	0.8	10
321	HES5 silencing is an early and recurrent change in prostate tumourigenesis. Endocrine-Related Cancer, 2015, 22, 131-144.	1.6	10
322	Neuromodulation in bladder dysfunction. Current Opinion in Obstetrics and Gynecology, 1998, 10, 395-399.	0.9	10
323	Effects of a new 5Î± reductase inhibitor (epristeride) on human prostate cell cultures. , 1997, 32, 259-265.		9
324	ENHANCED RECOVERY: FROM PRINCIPLES TO PRACTICE IN UROLOGY. BJU International, 2010, 105, 1199-1201.	1.3	9

#	Article	IF	Citations
325	Common genetic variants associated with disease from genomeâ€wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. BJU International, 2013, 111, 1148-1155.	1.3	9
326	Gleason drift in the <scp>NIHR P</scp>rotec<scp>T</scp> study. Histopathology, 2015, 66, 438-446.	1.6	9
327	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. International Journal of Molecular Epidemiology and Genetics, 2011, 2, 316-27.	0.4	9
328	Can We Accurately Identify Men With Low Risk Prostate Cancer?. Journal of Urology, 2008, 180, 1217-1218.	0.2	8
329	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. Cancer Causes and Control, 2013, 24, 39-45.	0.8	8
330	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial â€“ lessons learnt from CAP (Cluster randomised triAl of PSA testing for) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.4	8
331	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. Cancer Epidemiology, 2018, 52, 99-105.	0.8	8
332	Menâ€™s experiences of radiotherapy treatment for localized prostate cancer and its long-term treatment side effects: a longitudinal qualitative study. Cancer Causes and Control, 2021, 32, 261-269.	0.8	8
333	Trends in the use of radiotherapy and radical surgery for patients with bladder urothelial cell carcinoma in East Anglia, 1995-2006. BJU International, 2011, 108, 1106-1114.	1.3	7
334	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. European Journal of Cancer Prevention, 2013, 22, 121-125.	0.6	7
335	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. Statistical Methods in Medical Research, 2016, 25, 1875-1891.	0.7	7
336	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. British Journal of Cancer, 2017, 117, 734-743.	2.9	7
337	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. European Journal of Cancer Prevention, 2019, 28, 569-575.	0.6	7
338	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open, 2020, 10, e036024.	0.8	7
339	The morbidity of transurethral resection of the prostate. Current Opinion in Urology, 1996, 6, 147-150.	0.9	6
340	Stage migration and pilot studies of reduced chemotherapy supported by positron-emission tomography findings suggest new combined strategies for stage 2 nonseminoma germ cell tumour. BJU International, 2008, 101, 570-574.	1.3	6
341	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. Brain, Behavior, and Immunity, 2009, 23, 1073-1078.	2.0	6
342	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. BJU International, 2011, 108, 1409-1414.	1.3	6

#	Article	IF	Citations
343	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. Journal of Clinical Epidemiology, 2019, 113, 200-213.	2.4	6
344	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. PLoS ONE, 2015, 10, e0136735.	1.1	6
345	Regulation of the localisation and function of the oncogene LYRIC/AEGâ€1 by ubiquitination at K486 and K491. Molecular Oncology, 2014, 8, 633-641.	2.1	5
346	Prostateâ€specific antigen patterns in <scp>US</scp> and European populations: comparison of six diverse cohorts. BJU International, 2016, 118, 911-918.	1.3	5
347	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. Trials, 2016, 17, 497.	0.7	5
348	KLK3 SNPâ€“SNP interactions for prediction of prostate cancer aggressiveness. Scientific Reports, 2021, 11, 9264.	1.6	5
349	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. Neurourology and Urodynamics, 1995, 14, 359-363.	0.8	4
350	Including a 'no active intervention' arm in surgical trials is possible: evidence from the CLasP randomised trial. Journal of Health Services Research and Policy, 2003, 8, 209-214.	0.8	4
351	A model of the natural history of screen-detected prostate cancer. British Journal of Cancer, 2006, 95, 1122-1123.	2.9	4
352	Missing channels in two-colour microarray experiments: Combining single-channel and two-channel data. BMC Bioinformatics, 2007, 8, 26.	1.2	4
353	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. Cancer Epidemiology, 2011, 35, 139-144.	0.8	4
354	Predictors of the use of orthotopic bladder reconstruction after radical cystectomy for bladder cancer: data from a pilot study of 1756 cases 2004-2011. BJU International, 2013, 111, 1061-1067.	1.3	4
355	Kinase joins the chaperone club: Androgen-regulated kinome reveals choline kinase alpha as a potential drug target in prostate cancer. Molecular and Cellular Oncology, 2016, 3, e1140262.	0.3	4
356	Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer. European Urology, 2016, 70, 993-994.	0.9	4
357	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. Health Services and Delivery Research, 2015, 3, 1-138.	1.4	4
358	The first national clinical audit of prostate cancer care. BJU International, 2013, 112, 883-884.	1.3	3
359	Evaluation of Dendritic Cell Immunogenicity After Activation and Chemical Fixation: A Mixed Lymphocyte Reaction Model. Journal of Immunotherapy, 2002, 25, 152-161.	1.2	2
360	Where are we now with prostate cancer diagnosis?. Trends in Urology & Men's Health, 2010, 1, 18-20.	0.2	2

#	Article	IF	Citations
361	Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal, 2012, 31, 1617-1617.	3.5	2
362	Targeting the proâ€survival sideâ€effects of androgenâ€deprivation therapy in prostate cancer. BJU International, 2013, 111, 532-533.	1.3	2
363	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. Cancer Causes and Control, 2017, 28, 877-888.	0.8	2
364	The role of the Postgraduate Medical Education and Training Board (PMETB). Surgery, 2008, 26, 403-407.	0.1	1
365	Clarification of NICE Guidance on Prostate Cancer. British Journal of Medical and Surgical Urology, 2009, 2, 219-223.	0.2	1
366	Randomised surgical trials need good surgical outcomes in the control arm. BMJ: British Medical Journal, 2011, 343, d7520-d7520.	2.4	1
367	Prostate Cancer UK: the Blue Skies Forum. Trends in Urology & Men's Health, 2013, 4, 39-43.	0.2	1
368	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. Journal of Urology, 2000, , 630.	0.2	1
369	Non-invasive diagnosis. , 2007, , 39-49.		1
370	Clean intermittent self catheterization. International Urogynecology Journal, 1993, 4, 250-251.	0.7	0
371	Fibroblast Growth Factor Receptor (FGFR). Expert Opinion on Therapeutic Targets, 1997, 1, 173-175.	1.0	0
372	Molecular medicine and its impact on practice. Nature Reviews Urology, 2005, 2, 59-59.	1.4	0
373	Can a point-of-care proteomic assay increase the accuracy of cystoscopy?. Nature Reviews Urology, 2005, 2, 320-321.	1.4	0
374	Treatment for PSA screen-detected prostate cancer: what are the options?. Nature Reviews Urology, 2009, 6, 132-134.	1.9	0
375	Growing Teratoma Syndrome: A Case of Mistaken Identity. British Journal of Medical and Surgical Urology, 2011, 4, 272-275.	0.2	0
376	Role of the androgen receptor in prostate cancer. Trends in Urology & Men's Health, 2013, 4, 26-30.	0.2	0
377	Pre-malignant Disease in the Prostate. , 2011, , 467-491.		0
378	The Development of a Robotic Urology Program in the UK. , 2011, , 97-109.		0